Item 5.07 Submission of Matters to a Vote of Security Holders.
Deciphera Pharmaceuticals, Inc. (the Company) held its annual meeting (the Annual Meeting) of stockholders on
June 11, 2019. The following proposals were submitted to the stockholders at Annual Meeting:
(i) The election of two
Class II directors, as nominated by the Companys board of directors, each to serve a three-year term expiring at the 2022 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier
death, resignation or removal; and
(ii) The ratification of the appointment of PricewaterhouseCoopers LLP as the independent
registered public accounting firm of the Company for its fiscal year ending December 31, 2019.
The proposals are described in detail
in the Companys Proxy Statement filed with the Securities and Exchange Commission on April 22, 2019.
The number of shares of
common stock entitled to vote at the Annual Meeting was 38,189,052. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 36,605,982. All matters submitted to a vote of the Companys
stockholders at the Annual Meeting were approved and all director nominees were elected.
The number of votes cast for and against and the
number of abstentions and broker
non-votes
with respect to each matter voted upon are set forth below:
|
(a)
|
Election of Class II Directors.
|
|
|
|
|
|
Director Nominee
|
|
Votes For
|
|
Votes Withheld
|
Steven L. Hoerter
|
|
31,231,519
|
|
2,387,662
|
John R. Martin
|
|
29,648,870
|
|
3,970,311
|
There were 2,986,801 broker
non-votes
regarding the election of
directors.
|
(b)
|
Ratification of the appointment of PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the fiscal year ending December 31, 2019.
|
Stockholders ratified the appointment of
PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2019. The results of the voting included 36,579,379 votes for, 8,785 votes against and 17,818 votes
abstained. There were no broker
non-votes
regarding this proposal.
2